Our commitment to corporate governance underpins the trust that our investors, employees and institutions have in us. We maintain our efforts to build confidence as we continue to grow.

Management Board

Valneva’s Management Board is a highly dedicated international team, with diverse backgrounds, experience, expertise and skills.

Thomas Lingelbach President & Chief Executive Officer

CEO of Intercell since 2011, Managing Director for Novartis Vaccines & Diagnostics Germany, Vice President of Global Industrial Operations at Chiron Vaccines, more than 25 years in the vaccine industry.

Franck Grimaud President & Chief Business Officer

CEO and co-founder of Vivalis since 1999, formerly responsible for Groupe Grimaud’s development in Asia, 25 years in corporate business development and life sciences.

David Lawrence Chief Financial Officer

CFO of vaccine biotech company Acambis, Vice President Finance, Business Development and Strategy at Chiron Vaccines, Vice President Finance GSK, non-executive and advisory experience, 30 years of experience in vaccines and life sciences.

Wolfgang Bender, MD, PhD Chief Medical Officer

Senior international positions at various large life science companies including Novartis, Takeda, Pfizer and Hoechst, experiences in scientific-medical affairs, drug development and general management of vaccines and pharmaceuticals, more than 30 years of experience in life sciences.

Frederic Jacotot General Counsel and Corporate Secretary

VP Legal & IP and General Counsel of Valneva since September 2013, former Division Counsel at Abbott, 30 years as a legal expert in the pharmaceutical industry.

Supervisory Board

As part of Valneva’s two-tier corporate governance system, the Supervisory Board, acting in the interests of the shareholders, participates actively in reviewing the Company’s strategic options and setting direction together with the Management Board.

Frédéric Grimaud (F)

Chairman of Valneva’s Supervisory Board, Representative of the Company's largest shareholder, President and CEO of Groupe Grimaud.

Lisa Shaw-Marotto (U.S.)

Vice-Chairperson of the Supervisory Board & Chair - Nomination & Compensation Committee, President of Executive Perspective Consulting LLC, Former Vice President Marketing at Merck & Co.

James Sulat (U.S.)

Member of the Supervisory Board & Chair - Audit Committee, Former CFO for Chiron and CEO of Maxygen.

Anne-Marie Graffin (F)

Member of the Supervisory Board, Managing Director of SMAG Consulting, Supervisory Board member of Nanobiotix SA, Board member of Sartorius Stedim Biotech SA, Former Vice President at Sanofi Pasteur MSD.

Alexander Von Gabain Prof., PhD (A)

Member of the Supervisory Board, Chairman of the trans-European innovation consortium EITHealth, Former Vice-President of the Karolinska Institute, Co-founder of Intercell.

Balaji Muralidhar, MD, PhD (UK)

Member of the Supervisory Board, Partner at Abingworth, Former Partner at MVM Partners LLP, Former member of Bain Capital’s healthcare deal team.

Sandra E. Poole (U.S.)

Member of the Supervisory Board, Member of Board of Directors of Retrophin, Former COO at LogicBio Therapeutics, Former Executive Vice President, Technical Operations at ImmunoGen, Senior Vice President Biologics Manufacturing at Sanofi Genzyme.

Scientific Advisory Board

Valneva announced the formation of a Scientific Advisory Board (SAB) as part of the evolution of its governance structure in July 2019.

Dr. Ralf Clemens, MD, Ph.D. Chair

Member of Board of Trustees International Vaccine Institute IVI, member GHIT scientific selection committee, Advisor Bill & Melinda Gates Foundation, former Head/Senior Vice President Vaccine Development at GSK, Novartis and Takeda

Dr. Alain Munoz, MD, Ph.D.,

Board member of Hybrigenics SA, Supervisory Board member of OxThera AB, Zealand Pharma A/S, former SVP for international development at Sanofi, former SVP of the pharmaceutical division at Fournier Laboratories

Additional permanent members, complemented by ad-hoc members with strong expertise in specific areas, will join the SAB.